Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients

Bibliography

• Hickok JT, Roscoe JA, Morrow GR, 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 2005;6:765-72
   PubMed Web of Science ®Google Scholar
• Hofman M, Morrow GR, Roscoe JA, Cancer patients' expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center--Community Clinical Oncology Program study of 938 patients from community practices. Cancer 2004;101:851-7
   PubMed Web of Science ®Google Scholar
• Hickok JT, Morrow GW, Roscoe JA, Prevalence and severity of acute and delayed NV association with 3 highly emetogenic chemotherapies. [abstract]. Support Care in Cancer 2001;9:289
   Google Scholar
• Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol 2007;18:233-40
   PubMed Web of Science ®Google Scholar
• Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer 2005;13:117-21
   PubMed Web of Science ®Google Scholar
• Morrow GR, Roscoe JA, Kirshner JJ, Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer 1998;6:244-7
   PubMed Web of Science ®Google Scholar
• Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-94
   PubMed Web of Science ®Google Scholar
• Figueroa-Moseley C, Morrow GR. Major advances and alternative approaches to antiemetic therapy. Oncology 2008;21. Available at: www.cancernetwork.com/nausea-and-vomiting/article/10165/59693
   Web of Science ®Google Scholar
• Schwartzberg LS. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Oncology 2007;21:946-53
   PubMed Web of Science ®Google Scholar
• Grote T, Hajdenberg J, Cartmell A, Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006;4:403-8
   PubMedGoogle Scholar
• Wilhelm SM, Dehoorne-Smith ML, Kale-Pradhan PB. Prevention of postoperative nausea and vomiting. Ann Pharmacother 2007;41:68-78
   PubMed Web of Science ®Google Scholar
• Rhodes VA, McDaniel R. Nausea, vomiting, and retching: complex problems in palliative care. CA Cancer J Clin 2001;51:232-48
   PubMed Web of Science ®Google Scholar
• Sanger GJ, Andrews PL. Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci 2006;129:3-16
   PubMed Web of Science ®Google Scholar
• Ingle RJ, Burish TG, Wallston KA. Conditionability of cancer chemotherapy patients. Oncol Nurs Forum 1984;11:97-102
   PubMedGoogle Scholar
• Basch E, Prestrud AA, Hesketh PJ, Antiemetics: american society of clinical oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-98
   PubMed Web of Science ®Google Scholar
• Durand JP, Madelaine I, Scotte F. Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting. Bull Cancer 2009;96:951-60
   PubMed Web of Science ®Google Scholar
• Roila F, Boschetti E, Tonato M, Predictive factors of delayed emesis in cisplatintreated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 1991;14:238-42
   PubMed Web of Science ®Google Scholar
• Kris MG, Gralla RJ, Clark RA, Incidence, course, and severity of delayed nausea and vomiting following the administration of highdose cisplatin. J Clin Oncol 1985;3:1379-84
   PubMed Web of Science ®Google Scholar
• Roscoe JA, Morrow GR, Hickok JT, Biobehavioral factors in chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 2004;2:501-8
   PubMedGoogle Scholar
• Herrstedt J, Rapoport B, Warr D, Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer 2011;19(Suppl 1):S15-23
   Google Scholar
• Bloechl-Daum B, Deuson RR, Marvos P, Delayed nausea and vomiting continue to reduce patient's quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-8
   PubMed Web of Science ®Google Scholar
• Roscoe JA, Heckler CE, Morrow GR, Prevention of delayed nausea: a university of Rochester cancer center community clinical oncology program study of patients receiving chemotherapy. J Clin Oncol 2012;30:3389-95
   PubMed Web of Science ®Google Scholar
• Roscoe JA, Morrow GR, Aapro MS, Anticipatory nausea and vomiting. Support Care Cancer 2011;19(10):1533-8
   PubMed Web of Science ®Google Scholar
• Jacobsen PB, Redd WH. The development and management of chemotherapy-related anticipatory nausea and vomiting. Cancer Invest 1988;6:329-36
   PubMed Web of Science ®Google Scholar
• Moher D, Arthur AZ, Pater JL. Anticipatory nausea and/or vomiting. Cancer Treat Rev 1984;11:257-64
   PubMed Web of Science ®Google Scholar
• Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 1984;2:1170-6
   PubMed Web of Science ®Google Scholar
• Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 2007;12:1143-50
   PubMed Web of Science ®Google Scholar
• Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 2006;4:3-8
   PubMedGoogle Scholar
• Roscoe JA, Morrow GR, Aapro MS, Anticipatory nausea and vomiting. Support Care Cancer
   Google Scholar
• Nevidjon B, Chaudhary R. Controlling emesis: evolving challenges, novel strategies. J Support Oncol 2010;8:1-10
   PubMedGoogle Scholar
• Jacobsen PB, Redd WH. The development and management of chemotherapy-related anticipatory nausea and vomiting. Cancer Invest 1988;6:329-36
   PubMed Web of Science ®Google Scholar
• Moher D, Arthur AZ, Pater JL. Anticipatory nau sea and/or vomiting. Cancer Treat Rev 1984;11:257-64
   PubMed Web of Science ®Google Scholar
• Darmani NA, Ray AP. Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting. Chem Rev 2009;109:3158-99
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, VanBelle S, Aapro M, Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003;39:1074-80
   PubMed Web of Science ®Google Scholar
• Rudd JA, Andrews PL. Mechanisms of acute, delayed, and anticipatory emesis induced by anticancer therapies. Jones & Bartlett; Sudbury, MA: 2005
   Google Scholar
• Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 2011;22:30-8
   PubMed Web of Science ®Google Scholar
• Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001;111:106S-12S
   PubMed Web of Science ®Google Scholar
• Rubenstein EB, Slusher BS, Rojas C, Navari RM. New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J 2006;12:341-7
   PubMed Web of Science ®Google Scholar
• Hockenberry-Eaton M, Benner A. Patterns of nausea and vomiting in children: nursing assessment and intervention. Oncol Nurs Forum 1990;17:575-84
   PubMedGoogle Scholar
• Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-94
   PubMed Web of Science ®Google Scholar
• Rudd JA, Andrews PLR. editors. Chapter 2: Mechanisms of acute, delayed, and anticipatory emesis induced by anticancper therapies. Jones and Bartlett; Sudbury, MA; 2005
   Google Scholar
• Leslie RA, Reynolds DJM. Chapter 6: Neurotransmitters and receptors in the emetic pathway. Chapman & Hall Medical; London; 1993
   Google Scholar
• Blackshaw LA, Brookes SJ, Grundy D, Schemann M. Sensory transmission in the gastrointestinal tract. Neurogastroenterol Motil 2007;19:1-19
   PubMed Web of Science ®Google Scholar
• Burke CW, Mason JN, Surman SL, Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy. PLoS Pathog 2011;7
   PubMed Web of Science ®Google Scholar
• Lesurtel M, Soll C, Graf R, Clavien PA. Role of serotonin in the hepatogastrointestinal tract: an old molecule for new perspectives. Cell Mol Life Sci 2008;65:940-52
   PubMed Web of Science ®Google Scholar
• Gershon MD. Review article: serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004;20:3-14
   PubMed Web of Science ®Google Scholar
• Farber L, Haus U, Spath M, Drechsler S. Physiology and pathophysiology of the 5-HT3 receptor. Scand J Rheumatol Suppl 2004;119:2-8
   PubMedGoogle Scholar
• Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986;88:497-9
   PubMed Web of Science ®Google Scholar
• Higgins GA, Kilpatrick GJ, Bunce KT, 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 1989;97:247-55
   PubMed Web of Science ®Google Scholar
• del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 2000;89:2301-8
   PubMed Web of Science ®Google Scholar
• Palma C. Tachykinins and their receptors in human malignancies. Curr Drug Targets 2006;7:1043-52
   PubMed Web of Science ®Google Scholar
• Borison HL, McCarthy LE. Neuropharmacology of chemotherapy induced emesis. Drugs 1983;25:8-17
   PubMed Web of Science ®Google Scholar
• Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000;60:533-46
   PubMed Web of Science ®Google Scholar
• Girish C, Manikandan S. Aprepitant: a substance P antagonist for chemotherapy-induced nausea and vomiting. Indian J Cancer 2007;44:25-30
   PubMedGoogle Scholar
• Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008;5:32-42
   PubMedGoogle Scholar
• Saito R, Takano Y, Kamiya HO. Roles of substance P and NK(1) receptor in the brainstem in the development of emesis. J Pharmacol Sci 2003;91:87-94
   PubMed Web of Science ®Google Scholar
• Hu WP, You XH, Guan BC, Substance P potentiates 5-HT3 receptor-mediated current in rat trigeminal ganglion neurons. Neurosci Lett 2004;365:147-52
   PubMed Web of Science ®Google Scholar
• Minami M, Endo T, Yokota H, Effects of CP-99,994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT3 receptors. Eur J Pharmacol 2001;428:215-20
   PubMed Web of Science ®Google Scholar
• Darmani NA, Chebolu S, Amos B, Alkam T. Synergistic antiemetic interactions between serotonergic 5-HT(3) and tachykininergic NK(1)-receptor antagonists in the least shrew (Cryptotis parva). Pharmacol Biochem Behav 2011;99:573-9
   PubMed Web of Science ®Google Scholar
• Rojas C, Li Y, Zhang J, The antiemetic 5-HT3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 2010;335:362-8
   PubMed Web of Science ®Google Scholar
• Higa GM, Auber ML, Altaha R, Concordance between substance P levels and antiemetic guidelines. J Support Oncol 2009;7:138-42
   PubMedGoogle Scholar
• Darmani NA, Crim JL, Janoyan JJ, A re-evaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: evidence from the least shrew. Brain Res 2009;1248:40-58
   PubMed Web of Science ®Google Scholar
• Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 2009;69:515-33
   PubMed Web of Science ®Google Scholar
• Nausea and Vomiting (PDQ). 2012. Available from: http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/Patient/page1/AllPages/Print
   Google Scholar
• Matteson S, Roscoe J, Hickok J, Morrow GR. The role of behavioral conditioning in the development of nausea. Am J Obstet Gynecol 2002;186:S239-43
   PubMed Web of Science ®Google Scholar
• Stockhorst U, Enck P, Klosterhalfen S. Role of classical conditioning in learning gastrointestinal symptoms. World J Gastroenterol 2007;13:3430-7
   PubMed Web of Science ®Google Scholar
• Roscoe JA, Morrow GR, Aapro MS, Anticipatory nausea and vomiting. Support Care Cancer 2011;19:1533-8
   PubMed Web of Science ®Google Scholar
• Figueroa-Moseley C, Jean-Pierre P, Roscoe JA, Behavioral interventions in treating anticipatory nausea and vomiting. J Natl Compr Canc Netw 2007;5:44-50
   PubMedGoogle Scholar
• Morrow GR RJ, Hickok JT. Nausea and Vomiting. Oxford University Press; New York, NY; 1998
   Google Scholar
• (APA) APA. Diagnostic and statistical manual of mental disorders. 4th edition. Text rev; 2000
   Google Scholar
• Roscoe JA, Morrow GR, Aapro MS, Anticipatory nausea and vomiting. Support Care Cancer 2011;19:1533-8
   PubMed Web of Science ®Google Scholar
• Colagiuri B, Roscoe JA, Morrow GR, How do patient expectancies, quality of life, and postchemotherapy nausea interrelate? Cancer 2008;113:654-61
   PubMed Web of Science ®Google Scholar
• Hickok JT, Roscoe JA, Morrow GR. The role of patients' expectations in the development of anticipatory nausea related to chemotherapy for cancer. J Pain Symptom Manage 2001;22:843-50
   PubMed Web of Science ®Google Scholar
• Navari RM. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol 2010;6:1073-84
   PubMed Web of Science ®Google Scholar
• Aapro M, Grunberg S, Manikhas G, A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441
   PubMed Web of Science ®Google Scholar
• Saito M, Aogi K, Sekine I, Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10:115-24
   PubMed Web of Science ®Google Scholar
• Yu Z, Liu W, Wang L, The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer 2009;17:99-102
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Muss HB, Warr DG, Efficacy and tolerability of aprepitant for the prevention of chemotherapy induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-55
   PubMed Web of Science ®Google Scholar
• Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 2008;112:2080-7
   PubMed Web of Science ®Google Scholar
• EMEND (fosaprepitant dimeglumine) for injection. Merck & Co., Inc. 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022023s002s003s005lbl.pdf
   Google Scholar
• Langford P, Chrisp P. Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid 2010;5:77
   PubMedGoogle Scholar
• Strohscheer I, Borasio GD. Carbamazepine-responsive paroxysmal nausea and vomiting in a patient with meningeal carcinomatosis. Palliat Med 2006;20:549-50
   PubMed Web of Science ®Google Scholar
• Guttuso T Jr, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 2003;361:1703-5
   PubMed Web of Science ®Google Scholar
• Cruz FM, de Iracema Gomes Cubero D, Taranto P, Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study. Support Care Cancer 2012;20:601-6
   PubMed Web of Science ®Google Scholar
• Navari RM, Einhorn LH, Loehrer PJ Sr, A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 2007;15:1285-91
   PubMed Web of Science ®Google Scholar
• Navari RM, Einhorn LH, Passik SD, A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2005;13:529-34
   PubMed Web of Science ®Google Scholar
• Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011;9:188-95
   PubMedGoogle Scholar
• NCCN Clinical Practice Guidelines in Oncology: antiemetics. 2012. Available from: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf [Accessed 5 November 2012]
   Google Scholar
• Basch E, Hesketh PJ, Kris MG, Antiemetics: american society of clinical oncology clinical practice guideline update. J Oncol Pract Am Soc Clin Oncol 2011;7:395-8
   PubMedGoogle Scholar
• Basch E, Prestrud AA, Hesketh PJ, Antiemetics: american Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-98
   PubMed Web of Science ®Google Scholar
• MASCC/ESMO Antiemetic Guideline 2011. 2011. Available from: http://www.mascc.org/index.php?option=com_content&view=article&id=261 [Accessed 5 November 5 2012]
   Google Scholar
• Mustian KM, Devine KR, Ryan JL, Treatment of nausea and vomiting during chemotherapy. US Oncol Hematol 2011;7:91-7
   PubMedGoogle Scholar
• Mustian KM, Darling T, Janelsins MJ, Chemotherapy-induced nausea and vomiting. US Oncol 2008;4:19-23
   PubMedGoogle Scholar
• O'Kane A. Evaluate the effects Of implementing the Multinational Association Of Supportive Care In Cancer (MASCC) antiemetic guideline on the incidence of Chemotherapy-Induced Nausea And Vomiting (CINV) following platinum chemotherapy. Support Care Canr 2009;17:875
   Google Scholar
• Roila F, Warr D, Aapro M, Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only). Support Care Canrcer 2011;19(Suppl 1):S57-62
   PubMedGoogle Scholar